Indaptus Therapeutics, Inc. (INDP) analyst actions
Rating and price-target actions on INDP in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the INDP overview →
3 measured INDP analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab | Press release | +36.30% | -13.07% | |
| Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data | Press release | — | -2.31% | |
| Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort | Press release | -5.61% | +2.61% |
Keep exploring
More INDP: earnings → · SEC filings → · INDP overview →